Skip to main content

Mustang Bio, Inc. (MBIO)

NASDAQ: MBIO · IEX Real-Time Price · USD
2.23
+0.03 (1.36%)
After-hours:Oct 22, 2021 7:17 PM EDT
2.20
-0.01 (-0.45%)
At close: Oct 22, 4:00 PM
Market Cap197.42M
Revenue (ttm)-50,000
Net Income (ttm)-62.88M
Shares Out87.56M
EPS (ttm)-0.86
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume683,704
Open2.19
Previous Close2.21
Day's Range2.11 - 2.21
52-Week Range2.11 - 5.22
Beta1.71
AnalystsStrong Buy
Price Target10.40 (+372.7%)
Est. Earnings DateNov 5, 2021

About MBIO

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-107 and MB-207, a gene therapy program for X-linked severe combined immunodeficiency, a rare g...

IndustryBiotechnology
Employees62
Stock ExchangeNASDAQ
Ticker SymbolMBIO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for Mustang Bio stock is "Strong Buy." The 12-month stock price forecast is 10.40, which is an increase of 372.73% from the latest price.

Price Target
$10.40
(372.73% upside)
Analyst Consensus: Strong Buy

News

Mustang Bio to Participate in Chardan's Virtual 5th Annual Genetic Medicines Conference

WORCESTER, Mass., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell...

3 weeks ago - GlobeNewsWire

Mustang Bio Announces MB-101 (IL13Rα2‐targeted CAR T cells) Scientific Presentations at Upcoming Virtual Conferences

Christine Brown, Ph.D., of City of Hope will present at the First Annual Conference on CNS Clinical Trials Co-sponsored by SNO and ASCO and the AACR Virtual Special Conference: Brain Cancer Christine Br...

3 weeks ago - GlobeNewsWire

Mustang Bio (MBIO) Sees Hammer Chart Pattern: Time to Buy?

Mustang Bio (MBIO) has been struggling lately, but the selling pressure may be coming to an end soon.

4 weeks ago - Zacks Investment Research

Mustang Bio to Participate in Three September 2021 Investor Conferences

WORCESTER, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell...

1 month ago - GlobeNewsWire

Reddit Penny Stocks to Buy? 3 That You Probably Don't Know About

Reddit penny stocks are heating up, here's 3 to watch right now The post Reddit Penny Stocks to Buy? 3 That You Probably Don't Know About appeared first on Penny Stocks to Buy, Picks, News and Informati...

Other symbols:AEGBRFS
2 months ago - PennyStocks

Mustang Bio Reports Second Quarter 2021 Financial Results and Recent Corporate Highlights

WORCESTER, Mass., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell ...

2 months ago - GlobeNewsWire

Mustang Bio Collaborates with Mayo Clinic on Novel CAR T Technology

The exclusively licensed platform has potential application for any tumor target

2 months ago - GlobeNewsWire

Are These Penny Stocks Worth Watching This Week? 3 For Your List

Which penny stocks are investors watching this week? Here's 3 for your list The post Are These Penny Stocks Worth Watching This Week?

Other symbols:ANYCYTO
2 months ago - PennyStocks

5 Best Penny Stocks To Buy Right Now According To Insiders

These Penny Stocks Have Insiders Excited To Buy Right Now. The post 5 Best Penny Stocks To Buy Right Now According To Insiders appeared first on Penny Stocks to Buy, Picks, News and Information | PennyS...

Other symbols:APTOARCDPW
2 months ago - PennyStocks

3 Penny Stocks Insiders Are Buying

When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overa...

Other symbols:AMHGEMMA
2 months ago - Benzinga

Mustang Bio's Gene Therapy For Genetic Immunodeficiency Receives European PRIME Tag

The European Medicines Agency has granted Priority Medicines designation to Mustang Bio Inc's (NASDAQ: MBIO) MB-107 for X-linked severe combined immunodeficiency (X-SCID) in newly diagnosed infants, als...

2 months ago - Benzinga

Mustang Bio Receives European Medicines Agency PRIME Designation for MB-107 to Treat X-Linked Severe Combined Immunod...

WORCESTER, Mass., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell ...

2 months ago - GlobeNewsWire

Mustang Bio to Present at the Raymond James Human Health Innovation Conference

WORCESTER, Mass., June 16, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell ...

4 months ago - GlobeNewsWire

Best Penny Stocks To Buy? 4 To Watch This Week With Potential Catalysts

Penny stocks to watch with upcoming event dates to keep in mind this week The post Best Penny Stocks To Buy? 4 To Watch This Week With Potential Catalysts appeared first on Penny Stocks to Buy, Picks, N...

Other symbols:CYTRFBIOMEIPMTNBORPH
4 months ago - PennyStocks

5 Buy-Rated Stocks Trading Below $10 With Outstanding Upside Potential

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other symbols:IPWVTGNWDH
4 months ago - 24/7 Wall Street

Mustang Bio's CAR T Cell Therapy Achieves 93% ORR, 67% CR In Mid-Stage Leukemia Trial

Mustang Bio Inc (NASDAQ: MBIO) has updated interim data from the ongoing Phase 1/2 trial evaluating MB-106 for high-risk B-cell non-Hodgkin lymphomas (B-NHL) and chronic lymphocytic leukemia (CLL). The ...

4 months ago - Benzinga

Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106 CD20-Targeted CAR T in Patients with Relapsed or Refr...

Data presented at the European Hematology Association 2021 Virtual Congress show favorable safety profile and compelling clinical activity

4 months ago - GlobeNewsWire

Biotech Penny Stocks To Watch For June 2021

These penny stocks are expecting to release key information this month. The post Biotech Penny Stocks To Watch For June 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennySto...

Other symbols:APTOFBIORGLS
4 months ago - PennyStocks

Why Mustang Bio Stock Galloped Higher Today

The biotech announced a clinical update and an analyst initiated coverage on the stock.

5 months ago - The Motley Fool

5 Penny Stocks To Watch Right Now That Analysts Are Bullish On

Penny stocks remain volatile but these analysts have a bright outlook on these The post 5 Penny Stocks To Watch Right Now That Analysts Are Bullish On appeared first on Penny Stocks to Buy, Picks, News ...

Other symbols:BNGOEXPRGTBPMUX
5 months ago - PennyStocks

BTIG Sees 260% Upside In Mustang Bio With PT of $11; Early-Stage MB-101 Starts Dosing Brain Tumor Patients

Mustang Bio Inc (NASDAQ: MBIO) and the City of Hope, an independent cancer research and treatment center, have dosed the first patient in Phase 1 trial evaluating MB-101 in patients with leptomeningeal ...

5 months ago - Benzinga

Mustang Bio and City of Hope Announce First Patient Dosed in Phase 1 Clinical Trial of MB-101 (IL13Rα2-specific CAR T...

First dose occurred in trial underway at City of Hope to evaluate safety and feasibility of administering therapy in patients with brain tumors such as glioblastoma, ependymoma or medulloblastoma First ...

5 months ago - GlobeNewsWire

Mustang Bio Reports First Quarter 2021 Financial Results and Recent Corporate Highlights

WORCESTER, Mass., May 14, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell a...

5 months ago - GlobeNewsWire

Mustang Bio Announces MB-106 CD20-Targeted CAR T Data Selected for Presentation at European Hematology Association 20...

Fred Hutchinson Cancer Research Center to present updated interim data from ongoing MB-106 Phase 1/2 clinical trial Fred Hutchinson Cancer Research Center to present updated interim data from ongoing MB...

5 months ago - GlobeNewsWire

Mustang Bio Announces FDA Acceptance of IND Application for MB-106, a CD20-Targeted CAR T Therapy

The Phase 1/2 multicenter study to assess the safety, tolerability and efficacy of MB-106 in patients with relapsed or refractory CD20+ B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia is ex...

5 months ago - GlobeNewsWire